PortfoliosLab logoPortfoliosLab logo
Disc Medicine Inc. (IRON)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US2546041011
WKN
A3D063
IPO Date
Aug 12, 2020

Highlights

Market Cap
$2.26B
Enterprise Value
$2.17B
EPS (TTM)
-$6.03
Total Revenue (TTM)
-$19.88M
Gross Profit (TTM)
-$12.65M
EBITDA (TTM)
-$236.02M
Year Range
$30.82 - $99.50
Target Price
$110.25
ROA (TTM)
-26.30%
ROE (TTM)
-28.68%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Disc Medicine Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Disc Medicine Inc. (IRON) has returned -19.48% so far this year and 28.81% over the past 12 months.


Disc Medicine Inc.

1D
5.20%
1M
-4.02%
YTD
-19.48%
6M
-3.24%
1Y
28.81%
3Y*
44.50%
5Y*
-13.57%
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Aug 12, 2020, IRON's average daily return is +0.07%, while the average monthly return is +1.28%. At this rate, your investment would double in approximately 4.5 years.

Historically, 54% of months were positive and 46% were negative. The best month was Apr 2023 with a return of +54.5%, while the worst month was Apr 2024 at -55.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.

On a daily basis, IRON closed higher 49% of trading days. The best single day was Dec 30, 2022 with a return of +47.3%, while the worst single day was Apr 1, 2024 at -45.1%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-2.63%-13.84%-4.02%-19.48%
2025-11.99%0.68%-11.64%-0.44%-5.54%13.45%12.84%-0.19%10.79%30.48%8.28%-14.94%25.25%
202413.83%4.44%-9.33%-55.28%21.95%32.75%-4.24%17.75%-3.31%-8.79%41.57%-0.08%9.76%
202310.61%13.64%-15.24%54.46%13.44%19.58%11.71%6.75%-11.27%-2.49%20.45%4.68%190.40%
2022-32.65%-30.61%2.21%8.63%-15.23%32.03%-9.47%1.31%5.81%9.76%-4.44%15.64%-31.65%
20217.27%28.81%-10.86%-13.73%5.22%-47.40%-37.09%20.88%-17.89%-5.94%-27.37%5.43%-73.55%

Benchmark Metrics

Disc Medicine Inc. has an annualized alpha of 5.79%, beta of 0.83, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since August 13, 2020.

  • This stock participated in 172.25% of S&P 500 Index downside but only 97.96% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
5.79%
Beta
0.83
0.04
Upside Capture
97.96%
Downside Capture
172.25%

Return for Risk

Risk / Return Rank

IRON ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.


IRON Risk / Return Rank: 5656
Overall Rank
IRON Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
IRON Sortino Ratio Rank: 5555
Sortino Ratio Rank
IRON Omega Ratio Rank: 5757
Omega Ratio Rank
IRON Calmar Ratio Rank: 5353
Calmar Ratio Rank
IRON Martin Ratio Rank: 5656
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Disc Medicine Inc. (IRON) and compare them to a chosen benchmark (S&P 500 Index).


IRONBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.47

0.90

-0.42

Sortino ratio

Return per unit of downside risk

1.04

1.39

-0.35

Omega ratio

Gain probability vs. loss probability

1.15

1.21

-0.06

Calmar ratio

Return relative to maximum drawdown

0.55

1.40

-0.85

Martin ratio

Return relative to average drawdown

1.48

6.61

-5.12

Explore IRON risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Disc Medicine Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Disc Medicine Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Disc Medicine Inc. was 93.22%, occurring on May 26, 2022. The portfolio has not yet recovered.

The current Disc Medicine Inc. drawdown is 64.48%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.22%Mar 16, 2021304May 26, 2022
-15.99%Mar 3, 20214Mar 8, 20213Mar 11, 20217
-14.7%Sep 28, 202025Oct 30, 202047Jan 8, 202172
-10.52%Jan 15, 20219Jan 28, 20213Feb 2, 202112
-10.37%Feb 4, 20213Feb 8, 20219Feb 22, 202112

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Disc Medicine Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Disc Medicine Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for IRON in comparison with other companies in the Biotechnology industry. Currently, IRON has a P/B value of 3.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items